China Medical Systems of Shenzhen will gain Asia rights (ex-Japan) to a MRSA candidate from Destiny Pharma, a British company specializing in treatments for drug resistant infections. CMS contributed $4 million to Destiny’s recent $20.6 million IPO on London’s AIM exchange, and its parent added another $4 million. In return, CMS and Destiny have signed a binding framework agreement giving CMS the rights to develop and commercialize Destiny’s MRSA treatment, XF-73, in Asia.
